Pál Weihe
Pál Weihe has a total of 261 co-authors. Here are the top co-authors by number of shared publications:
- Philippe Grandjean
University of Southern Denmark
31 shared publications - Esben Budtz-Jørgensen
Department of Public Health, Section of Biostatistics, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
13 shared publications - Maria Skaalum Petersen
Faculty of Health Science, University of the Faroe Islands, Tórshavn, Faroe Islands
13 shared publications - Flemming Nielsen
Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, 5000 Odense, Denmark
11 shared publications - Clara Amalie Gade Timmermann
National Institute of Public Health, University of Southern Denmark, Studiestræde 6, København K, 1455, Denmark
5 shared publications - Anna L. Choi
Harvard School of Public Health, Boston, USA
4 shared publications
Latest Publications
- Open Access
- 15 May 2026
- Published by Taylor & Francis in International Journal of Circumpolar Health
- Vol. 85 (1) , 2672860
Correction of iodine intake estimates from salt in Faroese dietary scenarios: implications for iodine fortification strategies
Dear Editor,Extending our paper, The iodine content of Faroese food items to support iodine nutrition in the North Atlantic [1], we have identified an error in the handling of iodine in salt used i...
- 15 May 2026
- Published by Taylor & Francis in International Journal of Circumpolar Health
- Vol. 85 (1) , 2672860
Open AccessCorrection of iodine intake estimates from salt in Faroese dietary scenarios: implications for iodine fortification strategies
Dear Editor,Extending our paper, The iodine content of Faroese food items to support iodine nutrition in the North Atlantic [1], we have identified an error in the handling of iodine in salt used i...
- Open Access
- 17 April 2026
- Published by Elsevier in Environmental Research
- Vol. 301, 124535
Prenatal and childhood exposure to perfluoroalkyl substances and fat distribution in 9-year-old children: A prospective cohort study in the Faroe Islands
- 17 April 2026
- Published by Elsevier in Environmental Research
- Vol. 301, 124535
Open AccessPrenatal and childhood exposure to perfluoroalkyl substances and fat distribution in 9-year-old children: A prospective cohort study in the Faroe Islands
- Open Access
- 18 September 2024
- Published by Elsevier in Science of The Total Environment
- Vol. 954, 176274
Cross-cutting studies of per- and polyfluorinated alkyl substances (PFAS) in Arctic wildlife and humans
- 18 September 2024
- Published by Elsevier in Science of The Total Environment
- Vol. 954, 176274
Open AccessCross-cutting studies of per- and polyfluorinated alkyl substances (PFAS) in Arctic wildlife and humans
- Open Access
- 17 September 2023
- Published by Environmental Health Perspectives in ISEE Conference Abstracts
- Vol. 2023 (1)
Perfluoroalkyl Substances and Metabolic Dysregulations over the Life-course: A Longitudinal Metabolome Investigation using Causal Inference Framework
- 17 September 2023
- Published by Environmental Health Perspectives in ISEE Conference Abstracts
- Vol. 2023 (1)
Open AccessPerfluoroalkyl Substances and Metabolic Dysregulations over the Life-course: A Longitudinal Metabolome Investigation using Causal Inference Framework
- Top Cited PapersOpen Access
- 15 February 2023
- Published by Springer Nature in AMBIO
- Vol. 52 (5) , 877-896
Our evolved understanding of the human health risks of mercury
Mercury (Hg) is a chemical of health concern worldwide that is now being acted upon through the Minamata Convention. Operationalizing the Convention and tracking its effectiveness requires empathy of the diversity and variation of mercury exposure and risk in populations worldwide. As part of the health plenary for the 15th International Conference on Mercury as a Global Pollutant (ICMGP), this review paper details how scientific understandings have evolved over time, from tragic poisoning events in the mid-twentieth century to important epidemiological studies in the late-twentieth century in the Seychelles and Faroe Islands, the Arctic and Amazon. Entering the twenty-first century, studies on diverse source-exposure scenarios (e.g., ASGM, amalgams, contaminated sites, cosmetics, electronic waste) from across global regions have expanded understandings and exemplified the need to consider socio-environmental variables and local contexts when conducting health studies. We conclude with perspectives on next steps for mercury health research in the post-Minamata Convention era.
- 15 February 2023
- Published by Springer Nature in AMBIO
- Vol. 52 (5) , 877-896
Top Cited PapersOpen AccessOur evolved understanding of the human health risks of mercury
Mercury (Hg) is a chemical of health concern worldwide that is now being acted upon through the Minamata Convention. Operationalizing the Convention and tracking its effectiveness requires empathy of the diversity and variation of mercury exposure and risk in populations worldwide. As part of the health plenary for the 15th International Conference on Mercury as a Global Pollutant (ICMGP), this review paper details how scientific understandings have evolved over time, from tragic poisoning events in the mid-twentieth century to important epidemiological studies in the late-twentieth century in the Seychelles and Faroe Islands, the Arctic and Amazon. Entering the twenty-first century, studies on diverse source-exposure scenarios (e.g., ASGM, amalgams, contaminated sites, cosmetics, electronic waste) from across global regions have expanded understandings and exemplified the need to consider socio-environmental variables and local contexts when conducting health studies. We conclude with perspectives on next steps for mercury health research in the post-Minamata Convention era.
- Open Access
- 21 November 2022
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 31 (3) , 329-337
FarGen: Elucidating the distribution of coding variants in the isolated population of the Faroe Islands
Here we present results from FarGen Phase I exomes. This dataset is based on the FarGen cohort, which consists of 1,541 individuals from the isolated population of the Faroe Islands. The purpose of this cohort is to serve as a reference catalog of coding variants, and to conduct population genetic studies to better understand the genetic contribution to various diseases in the Faroese population. The first whole-exome data set comprise 465 individuals and a total of 148,267 genetic variants were discovered. Principle Component Analysis indicates that the population is isolated and weakly structured. The distribution of variants in various functional classes was compared with populations in the gnomAD dataset; the results indicated that the proportions were consistent across the cohorts, but probably due to a small sample size, the FarGen dataset contained relatively few rare variants. We identified 19 variants that are classified as pathogenic or likely pathogenic in ClinVar; several of these variants are associated with monogenetic diseases with increased prevalence in the Faroe Islands. The results support previous studies, which indicate that the Faroe Islands is an isolated and weakly structured population. Future studies may elucidate the significance of the 19 pathogenic variants that were identified. The FarGen Phase I dataset is an important step for genetic research in the Faroese population, and the next phase of FarGen will increase the sample size and broaden the scope.
- 21 November 2022
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 31 (3) , 329-337
Open AccessFarGen: Elucidating the distribution of coding variants in the isolated population of the Faroe Islands
Here we present results from FarGen Phase I exomes. This dataset is based on the FarGen cohort, which consists of 1,541 individuals from the isolated population of the Faroe Islands. The purpose of this cohort is to serve as a reference catalog of coding variants, and to conduct population genetic studies to better understand the genetic contribution to various diseases in the Faroese population. The first whole-exome data set comprise 465 individuals and a total of 148,267 genetic variants were discovered. Principle Component Analysis indicates that the population is isolated and weakly structured. The distribution of variants in various functional classes was compared with populations in the gnomAD dataset; the results indicated that the proportions were consistent across the cohorts, but probably due to a small sample size, the FarGen dataset contained relatively few rare variants. We identified 19 variants that are classified as pathogenic or likely pathogenic in ClinVar; several of these variants are associated with monogenetic diseases with increased prevalence in the Faroe Islands. The results support previous studies, which indicate that the Faroe Islands is an isolated and weakly structured population. Future studies may elucidate the significance of the 19 pathogenic variants that were identified. The FarGen Phase I dataset is an important step for genetic research in the Faroese population, and the next phase of FarGen will increase the sample size and broaden the scope.
- Open Access
- 23 June 2022
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 122, 437-441
Prevalence of long COVID in a national cohort: longitudinal measures from disease onset until 8 months’ follow-up
- 23 June 2022
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 122, 437-441
Open AccessPrevalence of long COVID in a national cohort: longitudinal measures from disease onset until 8 months’ follow-up
- Open Access
- 6 June 2022
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 9 (7) , ofac270
Long COVID in the Long Run—23-Month Follow-up Study of Persistent Symptoms
Symptoms of long coronavirus disease (COVID) were found in 38% of 170 patients followed for a median of 22.6 months. The most prevalent symptoms were fatigue, affected taste and smell, and difficulties remembering and concentrating. Predictors for long COVID were older age and number of symptoms in the acute phase. Long COVID may take many months, maybe years, to resolve.
- 6 June 2022
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 9 (7) , ofac270
Open AccessLong COVID in the Long Run—23-Month Follow-up Study of Persistent Symptoms
Symptoms of long coronavirus disease (COVID) were found in 38% of 170 patients followed for a median of 22.6 months. The most prevalent symptoms were fatigue, affected taste and smell, and difficulties remembering and concentrating. Predictors for long COVID were older age and number of symptoms in the acute phase. Long COVID may take many months, maybe years, to resolve.
- 13 April 2022
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 82 (3) , 251-256
Urine test strips and iodine contamination: a tricky trick in iodine nutrition surveys
A recent report from the Faroe Islands suggested mild iodine deficiency among women aged 40 years and older. New preliminary results showed an average urinary iodine concentration of 457 µg/L. This...
- 13 April 2022
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 82 (3) , 251-256
Urine test strips and iodine contamination: a tricky trick in iodine nutrition surveys
A recent report from the Faroe Islands suggested mild iodine deficiency among women aged 40 years and older. New preliminary results showed an average urinary iodine concentration of 457 µg/L. This...